Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves

Market Closed – Nasdaq			5-day change	1st Jan Change
7.040 ^USD	-5.25%		-10.32%	-15.59%

April 07, 2025 at 08:24 am EDT

This article is reserved for members

Unlock the article: REGISTER NOW!

Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher	08:40am	RE
Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves	08:24am	MT
Zevra Therapeutics Files Preliminary Proxy	Mar. 31	RE
Zevra Therapeutics Confirms Receipt of Director Nominees from Daniel J. Mangless	Mar. 31	CI
Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor	Mar. 31	MT
Sector Update: Health Care Stocks Lower Late Afternoon	Mar. 12	MT
Sector Update: Health Care Stocks Decline Wednesday Afternoon	Mar. 12	MT
Sector Update: Health Care	Mar. 12	MT
Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours	Mar. 11	MT
Zevra Therapeutics, Inc., Q4 2024 Earnings Call, Mar 11, 2025	Mar. 11
Zevra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 11	CI
Zevra Therapeutics to Sell Priority Review Voucher for $150 Million	Feb. 27	MT
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million	Feb. 27	DJ
An undisclosed buyer entered into a definitive asset purchase agreement to acquire Rare Pediatric Disease Priority Review Voucher of Zevra Therapeutics, Inc..	Feb. 26	CI
Zevra Therapeutics Insider Sold Shares Worth $727,390, According to a Recent SEC Filing	Feb. 14	MT
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to NASDAQ Biotechnology Index	Dec. 22	CI
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to S&P Pharmaceuticals Select Industry Index	Dec. 22	CI
Zevra Therapeutics to Join Nasdaq Biotechnology Index	Dec. 17	MT
Zevra Therapeutics, Inc. Announces Departure of Executives	Dec. 06	CI
Zevra Therapeutics, Inc. Announces U.S. Commercial Availability of MIPLYFFA for Treatment of Niemann-Pick Disease Type C	Nov. 21	CI
Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q3 Revenue $3.7M	Nov. 12	MT
Zevra Therapeutics, Inc., Q3 2024 Earnings Call, Nov 12, 2024	Nov. 12
Zevra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 12	CI
Guggenheim Initiates Zevra Therapeutics With Buy Rating, $20 Price Target	24-10-07	MT
JMP Securities Initiates Zevra Therapeutics at Outperform	24-09-24	MT

Duration

Period

ZVRA: Dynamic Chart

Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company’s lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.

More about the company

Sell

Buy

Last Close Price

7.040USD

Average target price

21.62USD

Spread / Average Target

+207.17%

Consensus

Exclusive-US Health Secretary Kennedy to address Gavi vaccine event amid funding pullback

Tesla seeks to keep Texas robotaxi data under wraps, regulator says

Oil prices are now the stock market’s biggest driver

Tesla shares soar after first robotaxi rides hit the road in Austin, Texas

Fed’s Bowman open to cutting rates at July policy meeting

Fiserv shares rise on stablecoin launch plans

Top Premarket Decliners | MarketScreener

Commercial Metals misses Q3 revenue estimates

Amazon’s premium beauty push may be a buffer against Trump’s tariffs

Caution on Bitcoin (BTC) Double Top, But a Full-Blown Price Crash Seems Unlikely, Sygnum’s Tischhauser Says

Today many options on Bitcoin and Ethereum are expiring.

Amazing AI PLC Announces Bitcoin Treasury Policy Update

Bitcoin Near All-Time Highs Spurs Record Long-Term Holder Supply Increase

Ethereum Foundation Drops 9,000 ETH in Past Month – What’s Happening?

Bitcoin ETFs Notch 13 Consecutive Days of Inflow—Why It Matters

Exclusive-US Health Secretary Kennedy to address Gavi vaccine event amid funding pullback

Tesla seeks to keep Texas robotaxi data under wraps, regulator says

Oil prices are now the stock market’s biggest driver

Tesla shares soar after first robotaxi rides hit the road in Austin, Texas

Fed’s Bowman open to cutting rates at July policy meeting

Fiserv shares rise on stablecoin launch plans

Top Premarket Decliners | MarketScreener

Commercial Metals misses Q3 revenue estimates

Amazon’s premium beauty push may be a buffer against Trump’s tariffs

Caution on Bitcoin (BTC) Double Top, But a Full-Blown Price Crash Seems Unlikely, Sygnum’s Tischhauser Says

Today many options on Bitcoin and Ethereum are expiring.

Amazing AI PLC Announces Bitcoin Treasury Policy Update

Bitcoin Near All-Time Highs Spurs Record Long-Term Holder Supply Increase

Ethereum Foundation Drops 9,000 ETH in Past Month – What’s Happening?

Bitcoin ETFs Notch 13 Consecutive Days of Inflow—Why It Matters

Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves

Related Posts

Caution on Bitcoin (BTC) Double Top, But a Full-Blown Price Crash Seems Unlikely, Sygnum’s Tischhauser Says

Today many options on Bitcoin and Ethereum are expiring.

Stock Market News Today, 6/27/25 – Stock Futures Climb to New Highs, Inflation Data in Focus

ForexLive European FX news wrap: Markets stay in retreat but pick up a little, for now

Yahoo Finance community reacts to Trump tariff stock market plunge

‘We’ll still go lower from here’ – DL News

Recent Posts

Navigate Site

Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves

Related Posts

Recent Posts

Navigate Site

Follow Us